Different gene-editing proteins have been used to edit the constant regions of the TCR α or β chains, or to disrupt the HLA-A locus of the MHC gene complex of the donor T-cells to interfere with TCR function or MHC class I expression to generate “universal” T-cells and eliminate off-tumour effects. The gene discussed is HLA-C; the disease is neoplasm.